Sfoglia per AUTORE
MUSTO P
Collezione AO Cuneo

  

Items : 10

End of induction [(18)F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial. in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2024 Sep;51(11):3311-3321. doi: 10.1007/s00259-024-06765-z. Epub 2024 Ma

2024
AOU Alessandria
AO Cuneo

Usai SV; Vitolo U; Falcinelli F; Gini G; Galimberti S; Roti G; Mannina D; Musto P; Conconi A; Massaia M; Bari A; Califano C; Arcari A; Chiarenza A; Pavone V; Bolis SAM; Bianchi B; Tosi P; Musuraca G; Ladetto M; Barbieri E; Monaco L; Franceschetto A; Peano S; Durmo R; Marcheselli L; Bergesio F; Fallanca F; Chauvie S; et alii...

Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial. in Blood cancer journal / Blood Cancer J. 2024 Aug 21;14(1):141. doi: 10.1038/s41408-024-01116-5.

2024
AO Cuneo
AOU Città della Salute di Torino

Iori AP; Bernasconi P; Corradini P; Russo D; Nagler A; Carella AM; Marotta G; Cerretti R; Rivela P; Terruzzi E; Saporiti G; Pane F; Patriarca F; Saccardi R; Musto P; Chiusolo P; Olivieri A; Milone G; Santarone S; Borghero C; Cavattoni IM; Busca A; Micò MC; Pavoni C; Grassi A; Cavallaro G; Castagna L; Mordini N; Oldani E; et alii...

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. in Blood advances / Blood Adv. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691.

2022
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Corradini P; Merli F; Passamonti F; Candoni A; Krampera M; Venditti A; Selleri C; Tosi P; Lanza F; Conconi A; La Barbera EO; Gambacorti-Passerini C; Visani G; Vallisa D; Rigacci L; Armiento D; Gherlinzoni F; Tafuri A; Galimberti S; Bocchia M; Corso A; Cilloni D; Cardinali V; Turrini M; Trentin L; Cuneo A; Della Porta M; Massaia M; Fracchiolla N; et alii...

Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV. in Hematological oncology / Hematol Oncol. 2022 Dec;40(5):846-856. doi: 10.1002/hon.3048. Epub 2022 Aug 12.

2022
AO Cuneo
AOU Città della Salute di Torino

Corradini P; Passamonti F; Antonio Grossi P; Bruno R; Pagano L; Luppi M; Busca A; Giuliani N; Corso A; Mohamed S; Tosi P; Giovanni Della Porta M; Lanza F; Rigacci L; Massimo Lemoli R; Venditti A; Tafuri A; Billio A; Gentile M; Falini B; Turrini M; Chiara Tisi M; Morotti A; Coviello E; Trentin L; Bocchia M; Galimberti S; Cuneo A; Musto P; et alii...

COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. in British journal of haematology / Br J Haematol. 2021 Nov;195(3):371-377. doi: 10.1111/bjh.17704. Epub 2021 Jul 16.

2021
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Corradini P; Pagano L; Grossi PA; Bertù L; Zaja F; Musto P; Petrucci L; Lanza F; Visani G; Mina R; La Barbera EO; Cattaneo C; Candoni A; Krampera M; Luppi M; Cardinali V; Galimberti S; Armiento D; Bocchia M; Marchesi F; Fracchiolla N; Tafuri A; Pinto A; Arcaini L; Massaia M; Ladetto M; Busca A; Venditti A; Farina F; et alii...

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.

2021
AO Cuneo
AOU Città della Salute di Torino

Petrucci MT; Gamberi B; Zambello R; Palmas A; de Fabritiis P; Aquino S; Giuliani N; Capra A; D'Agostino M; Patriarca F; Spadano A; Cea M; Ballanti S; Ledda A; Grasso M; Zamagni E; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F; Corradini P; Cavo M; Boccadoro M;

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. in The Lancet. Haematology / Lancet Haematol. 2020 Oct;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9. Epub 2020 Aug 13.

2020
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Corradini P; Pagano L; Bertù L; Corrao G; Grossi PA; Franchi M; Oberti M; Zappasodi P; Visco C; Armiento D; Pane F; Pinto A; Galieni P; Rigacci L; Candoni A; Venditti A; Fava C; Federici AB; Marchesi F; Musto P; Gentile M; Bocchia M; Di Renzo N; Olivieri A; Ferrandina C; Selleri C; Ortu La Barbera E; Luppi M; Scattolin AM; et alii...

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. in Blood cancer journal / Blood Cancer J. 2020 May 18;10(5):58. doi: 10.1038/s41408-020-0326-1.

2020
ASL Asti
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Romano A; Sonneveld P; Ria R; Musto P; Liberati AM; Offidani M; Giuliani N; Marchetti M; Mosca-Siez ML; de Fabritiis P; Gobbi M; Ballanti S; Cellini C; Grasso M; Monaco F; Ronconi S; Pescosta N; Di Lullo G; Capra A; Belotti A; Petrucci MT; Boccadoro M; Zambello R; Mina R;

Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study. in Haematologica / Haematologica. 2019 Jan;104(1):e4-e8. doi: 10.3324/haematol.2017.183590. Epub 2018 Aug 3.

2019
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino

Santini V; Levis A; Musto P; Tassara R; Finelli C; Saglio G; Bonferroni M; Allione B; Balleari E; Poloni A; Cametti G; Ferrero D; Sanna A; Ceccarelli M; Salvi F; Danise P; Masiera E; Castiglione A; Gioia D; Messa E; Messa E; Gioia D; Masiera E; Castiglione A; Ceccarelli M; Salvi F; Danise P; Sanna A; Allione B; et alii...

The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma). in Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) / Phys Med. 2016 May;32(5):651-6. doi: 10.1016/j.ejmp.2016.04.004. Epub 2016 Apr 28.

2016
AO Cuneo

Martelli M; Rigacci L; Balzarotti M; Cabras MG; Luminari S; Musto P; Storto G; Guerra L; Versari A; Biggi A; Brambilla M; Fioroni F; Bergesio F; Chauvie S; Vitolo U; Federico M; Gallamini A;